SRX-25

all catalysts(0)

nothing on the calendar yet

News(7)

• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 4d ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 25d ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 27d ago
• Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
  With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.
  biospace · 29d ago
• J&J sees Spravato sales surge as psychedelic competitors loom
  Psychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.
  biospace · 29d ago
• Another big premium hike on the horizon
  FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
  stat · 1mo ago
• Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
  The psychedelics field is getting what it has long wanted. Now it has to step up.
  stat · 3mo ago